Paško Konjevoda

Dr. Paško Konjevoda

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Medical Science Monitor
Verified
Journal Article
Open access
PDF file
JPJasminka Pavelić
Jasminka Pavelić
SČSrđana Čulić
Srđana Čulić
ISIlza Salamunić
Ilza Salamunić
PKPaško Konjevoda
Paško Konjevoda
SDSlavica Dajak
Slavica Dajak
Background:Immune thrombocytopenia (ITP) is an immune-mediated platelet disorder in which autoantibody-coated platelets are removed from the blood by monocytic phagocytes and there is impaired platelet production. There is a delicate balance of speci...

1 May 2018 in Toxicon
Verified
Journal Article
Closed access
DRDubravka Rašić
Dubravka Rašić
MMMarin Mladinić
Marin Mladinić
DŽDavor Želježić
Davor Želježić
Alica PizentAlica Pizent
Alica Pizent
SSSrđan Stefanović
Srđan Stefanović
MPMaja Peraica
Maja Peraica

1 January 2012 in Clinical Biochemistry
Verified
Journal Article
Closed access
DRDinko Rogulj
Dinko Rogulj
PKPaško Konjevoda
Paško Konjevoda
Mirta MilićMirta Milić
Mirta Milić
MMMarin Mladinić
Marin Mladinić
ADAna-Marija Domijan
Ana-Marija Domijan

1 April 2012 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
SMSilvana Miskovic
Silvana Miskovic
VCVida Culic
Vida Culic
PKPaško Konjevoda
Paško Konjevoda
JPJasminka Pavelic
Jasminka Pavelic

1 October 2015 in Pharmacological Reports
Verified
Journal Article
Closed access
MMMarija Macan
Marija Macan
AVAntonija Vukšić
Antonija Vukšić
SŽSuzana Žunec
Suzana Žunec
PKPaško Konjevoda
Paško Konjevoda
JLJasna Lovrić
Jasna Lovrić
VBVlasta Bradamante
Vlasta Bradamante

1 February 2018 in BioSystems
Verified
Journal Article
Open access
NŠNikola Štambuk
Nikola Štambuk
PKPaško Konjevoda
Paško Konjevoda
PTPetra Turčić
Petra Turčić
KKKatalin Kövér
Katalin Kövér
RKRenata Novak Kujundžić
Renata Novak Kujundžić
MGMario Gabričević
Mario Gabričević
Sense and antisense peptides, i.e. peptides specified by complementary DNA and RNA sequences, interact with increased probability. Biro, Blalock, Mekler, Root-Bernstein and Siemion investigated the recognition rules of peptide-peptide interaction based on the complementary coding of DNA and RNA sequences in 3'→5' and 5'→3' directions. After more than three decades of theoretical and experimental investigations, the efficiency of this approach to predict peptide-peptide binding has been experimentally verified for more than 50 ligand-receptor systems, and represents a promising field of research. The natural genetic coding algorithm for sense and antisense peptide interactions combines following elements: of amino acid physico-chemical properties, stereochemical interaction, and bidirectional transcription. The interplay of these factors influences the specificity of sense-antisense peptide interactions, and affects the selection and evolution of peptide ligand-receptor systems. Complementary mRNA codon-tRNA anticodon complexes, and recently discovered Carter-Wolfenden tRNA acceptor-stem code, provide the basis for the rational modeling of peptide interactions based on their hydrophobic and lipophilic amino acid physico-chemical properties. It is shown that the interactions of complementary amino acid pairs according to the hydrophobic and lipophilic properties strongly depend on the central (second) purine base of the mRNA codon and its pyrimidine complement of the tRNA anticodon. This enables the development of new algorithms for the analysis of structure, function and evolution of protein and nucleotide sequences that take into account the residue's tendency to leave water and enter a nonpolar condensed phase considering its mass, size and accessible surface area. The practical applications of the sense-antisense peptide modeling are illustrated using different interaction assay types based on: microscale thermophoresis (MST), tryptophan fluorescence spectroscopy (TFS), nuclear magnetic resonance spectroscopy (NMR), and magnetic particles enzyme immunoassay (MPEIA). Various binding events and circumstances were considered, e.g., in situations with-short antisense peptide ligand (MST), L- and D-enantiomer acceptors (TFS), in low affinity conditions (NMR), and with more than one antisense peptide targeting hormone (MPEIA).